Catalyst Wire Dossier Catalyst Wire Dossier

KS2422

CD80-modified allogeneic cancer cell line · University Hospital Tuebingen
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KS2422, covering 2010-05-20 to 2010-05-20. Get the full timeline:

Most recent: Clinical Trial Update: Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422) [Phase 1]

See pricing